|
Vaccine Detail
T. cruzi DNA Vaccine encoding G2 Protein |
Vaccine Information |
- Vaccine Name: T. cruzi DNA Vaccine encoding G2 Protein
- Target Pathogen: Trypanosoma cruzi
- Target Disease: Chagas disease
- Type: DNA vaccine
- Status: Research
- G2
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- DNA vaccine plasmid:
- DNA vaccine plasmid name:
- DNA vaccine plasmid VO ID: VO_0000132
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Mouse Response
- Host Strain: C57BL/6
- Vaccination Protocol: C57BL/6 mice were injected in the quadriceps muscle thrice at 2-week intervals with antigen-encoding plasmid (pCDNA3.TcG2 25 μg per DNA/mouse) and cytokine-encoding plasmids (pcDNA3.msp35, pcDNA3.msp40 [IL-12], and pCMVI.GM-CSF; 25 μg per plasmid DNA/mouse) (Bhatia and Garg, 2008).
- Challenge Protocol: Two weeks after the last immunization, mice were challenged with culture-derived T. cruzi trypomastigotes (2.5 × 10^4/mouse, intraperitoneally) and sacrificed at days 30, 75, and 120 postinfection (p.i.), corresponding to the acute phase of peak parasitemia, the intermediate phase of immune control of parasites, and the chronic phase of disease development, respectively (Bhatia and Garg, 2008).
- Efficacy: The dominant IgG2b/IgG1 antibody response was maintained after a challenge infection and was associated with 50% control of the acute-phase tissue parasite burden and an almost undetectable level of tissue parasites during the chronic phase (Bhatia and Garg, 2008).
|
References |
Bhatia and Garg, 2008: Bhatia V, Garg NJ. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clinical and vaccine immunology : CVI. 2008; 15(8); 1158-1164. [PubMed: 18550728].
|
|